Review

Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit?
Joan S Lewis-Wambi and V Craig Jordan

Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA

Corresponding author: Joan S Lewis-Wambi, joan.lewis@fccc.edu

Published: 29 May 2009
This article is online at http://breast-cancer-research.com/content/11/3/206
© 2009 BioMed Central Ltd

Abstract
The link between estrogen and the development and proliferation of breast cancer is well documented. Estrogen stimulates growth and inhibits apoptosis through estrogen receptor-mediated mechanisms in many cell types. Interestingly, there is strong evidence that estrogen induces apoptosis in breast cancer and other cell types. Forty years ago, before the development of tamoxifen, high-dose estrogen was used to induce tumor regression of hormone-dependent breast cancer in post-menopausal women. While the mechanisms by which estrogen induces apoptosis were not completely known, recent evidence from our laboratory and others demonstrates the involvement of the extrinsic (Fas/FasL) and the intrinsic (mitochondria) pathways in this process. We discuss the different apoptotic signaling pathways involved in E2 (17β-estradiol)-induced apoptosis, including the intrinsic and extrinsic apoptosis pathways, the NF-κB (nuclear factor-kappa-B)-mediated survival pathway as well as the PI3K (phosphoinositide 3-kinase)/Akt signaling pathway. Breast cancer cells can also be sensitized to estrogen-induced apoptosis through suppression of glutathione by BSO (L-buthionine sulfoximine). This finding has implications for the control of breast cancer with low-dose estrogen and other targeted therapeutic drugs.

Introduction
Breast cancer is one of the most frequently diagnosed cancers among women, with an estimated 184,450 new cases of invasive disease and 40,930 deaths in 2008. There is strong evidence that estrogen plays a role in its development and progression [1]. Breast cancer was first recognized to be estrogen-dependent when the British surgeon George Beatson [2] published his findings of the beneficial effects of oophorectomy in a pre-menopausal patient with advanced breast cancer. Beatson had based his approach on the role of the ovaries in mammalian lactation and presumed that there would be a similar mechanism for breast cancer growth. Since that time, there has been an expanding clinical database that implicates estrogen in the development and progression of breast cancer. Evidence to support this conclusion comes from clinical studies of hormone replacement therapy, which were initially designed to determine the benefits of replacement approaches on post-menopausal women’s health [3,4], and the successful clinical strategy of treating breast cancer by blocking estrogen action using the anti-estrogen tamoxifen [5] or preventing estrogen synthesis using aromatase inhibitors (AIs) [6].

Estrogens are a class of sex steroid hormones that are synthesized from cholesterol and are secreted primarily by the ovaries, with secondary contributions from placenta, adipose tissue, testes, and adrenal glands. After menopause, ovarian estrogen biosynthesis is minimal, with circulating estrogens being derived principally from peripheral aromatization of adrenal androgens. Estrogens are essential to the function of the female reproductive system and are required for the proliferation and differentiation of healthy breast epithelium. Estrogens occur naturally in several structurally related forms; however, the predominant intracellular estrogen is 17β-estradiol (E2). In mammary glands, E2 promotes cell proliferation in both normal and transformed epithelial cells by modifying the expression of hormone-responsive genes involved in the cell cycle and/or programmed cell

AI = aromatase inhibitor; AP-1 = activator protein 1; Bad = Bcl-2/Bcl-XL-associated death domain protein; Bak = Bcl-2 homologous antagonist-killer protein; Bax = Bcl-2-associated X protein; Bcl-2 = B-cell lymphoma-2; Bcl-2-related gene, long form; BH = Bcl-2 (B-cell lymphoma-2) homology; Bid = Bcl-2-interacting domain; Bim = Bcl-2-interacting mediator of cell death; BSO = L-buthionine sulfoximine; CDK = cyclin-dependent kinase; CR = complete response; DES = diethylstilbestrol; E2 = 17β-estradiol; ER = estrogen receptor; FasL = Fas ligand; GSH = glutathione; IL = interleukin; JNK = c-jun N-terminal kinase; LTED = long-term estrogen-deprived; MAPK = mitogen-activated protein kinase; NF-κB = nuclear factor-kappa-B; OPG = osteoprotegerin; PARP = poly(ADP-ribose)polymerase; PI3K = phosphoinositide 3-kinase; PKB/Akt = protein kinase B; PKC-α = protein kinase C-alpha; Puma = p53-upregulated modulator of apoptosis; RANK-L = ligand of the receptor activator of nuclear factor-kappa-B; SERM = selective estrogen receptor modulator; siRNA = short interfering RNA; Sp-1 = specificity protein 1; TNF = tumor necrosis factor.
death. In estrogen receptor (ER)-positive MCF-7 human breast cancer cells, one of the principal mechanisms by which E2 stimulates growth is through the induction of G1- to S-phase transition. This induction is associated with the rapid and direct upregulation of c-myc, which controls cyclin D1 expression along with activation of cyclin-dependent kinase (CDK) and phosphorylation of retinoblastoma protein [7]. E2 also rapidly activates cyclin E-CDK2 complexes, accelerating the G1-to-S transition [8]. Additionally, E2 has ‘non-genomic or membrane-initiated’ effects (that is, independent of ER-mediated transcription) that occur within minutes after E2 administration [9-11]. Specifically, ER-α interacts with a number of proteins, including c-Src, the p85 subunit of phosphoinositide 3-kinase (PI3K), caveolin 1, and modulator of non-genomic activity of ER (MNAR) [10,12], epidermal growth factor receptor (EGFR), insulin-like growth factor receptor 1 (IGFR1), and HER2 [13], and it rapidly increases PI3K-phospholipase C activity and activates the mitogen-activated protein kinase (MAPK) and PI3K/Akt pathways [9,12,13]. More importantly, E2 is a potent inhibitor of apoptosis and it regulates the expression of several apoptotic proteins, including Bcl-2 in MCF-7, T47-D, and ZR-75-1 breast cancer cells [14].

Remarkably, there is another dimension to estrogen action which contrasts with its ability to stimulate growth and inhibit apoptosis. Physiologic E2 is also capable of inducing apoptosis in breast cancer cells that have been long-term estrogen-deprived (LTED) or have been treated exhaustively with anti-estrogens [15-23], prostate cancer cells [24], neuronal cells [25], bone-derived cells [26], thymocytes [27], and ER-transfected cells [28,29]. These data are particularly interesting because high-dose estrogen therapy was used as a treatment for post-menopausal patients with metastatic breast cancer from the 1940s until the introduction of the safer anti-estrogen tamoxifen in the 1970s [30]. At that time, however, the mechanism of estrogen-induced tumor regression was not known. In this review, we will discuss the current understanding of estrogen-induced apoptosis in breast cancer and will summarize the possible mechanisms involved in this estrogen-mediated process.

**Estrogen-induced apoptosis: laboratory observations**

Recent in vitro studies from our laboratory [18,31] and other investigators [19,20,32] have shown that long-term estrogen deprivation of hormone-dependent MCF-7 breast cancer cells causes them to undergo adaptive changes in which estradiol switches from being a proliferative agent to paradoxically inhibiting growth and inducing apoptosis. Interestingly, LTED cells also exhibit enhanced sensitivity to estradiol in that an estradiol concentration that is three logs lower can stimulate proliferation of these cells compared with wild-type MCF-7 cells [19]. The development of hypersensitivity to estradiol as a result of LTED is associated with the upregulation of ER-α and the MAPK, PI3K, and mTOR (mammalian target of rapamycin) growth factor pathways [33]. In contrast, the apoptotic mechanisms of estradiol in LTED cells are thought to involve the death receptors as well as the mitochondrial pathways. Specific molecular events include the activation of the Fas death receptor/Fas ligand (FasL) complex [20], the release of cytochrome c from the mitochondria and alterations in Bcl-2 [18,32], and the downregulation of the anti-apoptotic factor nuclear factor-κ [31,34]. It is important to note that estradiol also induces apoptosis in in vivo models of anti-hormone drug resistance [23,35,36]; however, the mechanisms by which this occurs are not completely known.

**Estrogen therapy and breast cancer: clinical observations**

Clinical data support the use of high-dose estrogen to treat hormonally sensitive breast tumors [37-41]. In 1944, Sir Alexander Haddow and colleagues [37] published the results of their clinical trial with the synthetic estrogens triphenylchloretylene, triphenylmethylethylene, and stilbestrol administered at high doses. They found that 10 out of 22 post-menopausal patients with advanced mammary carcinomas, who were treated with triphenylchloretylene, had significant regression of tumor growth. Five patients out of 14 who were treated with high-dose stilbestrol produced similar responses. Interestingly, the duration of the post-menopausal period was found to be a critical factor affecting the success of this therapy. For example, when the synthetic estrogen diethylstilbestrol (DES) was administered at 15 mg per day, women who had experienced the onset of menopause less than 1 year prior to therapy did not respond to DES; women who had experienced the onset of menopause within 5 years of menopause experienced a 7.9% objective response rate; and women who reached menopause more than 10 years earlier experienced a 22% response rate [41]. Despite the benefits, however, there were significant systemic side effects associated with high-dose estrogen therapy [37].

Cole and colleagues [39] reported the first clinical trial of the anti-estrogen tamoxifen in women with late or recurrent breast cancer and compared their findings with historical data from women receiving DES. They concluded that the levels of response were similar for DES and tamoxifen; however, tamoxifen had a lower incidence of side effects. Ingle and colleagues [30] compared tamoxifen with DES directly and noted that response rates were similar but tamoxifen had fewer side effects. Based on these data, the use of high-dose estrogen for treatment of advanced breast cancer fell out of favor, and tamoxifen became the standard first-line endocrine therapy. The Ingle study [30] that compared DES-treated and tamoxifen-treated patients was followed up but surprisingly showed a survival advantage for DES-treated patients [41]. Another small trial was conducted by Lonning and colleagues [40] in post-menopausal patients with advanced breast cancer exposed to multiple endocrine therapies and revealed a 31% objective response rate with DES therapy. More recently, Ellis and colleagues [42]
reported that a daily dose of 6 mg of E2 could stop the growth of tumors or even cause them to shrink in about 25% of women with metastatic breast cancer that had developed resistance to standard anti-hormonal therapy. These clinical observations that estrogen can induce tumor regression after several years of anti-hormonal therapy provide a clue that the adaptation of cancer cells to low levels of estrogen might sensitize cells to the apoptotic effect of estrogen. While the mechanisms by which estrogen exerts its pro-apoptotic/anti-tumor effect are not known, a growing body of evidence suggests the involvement of the extrinsic (death receptor) and intrinsic (mitochondrial) pathways in this process.

**Two main pathways involved in apoptosis regulation**

Apoptosis is a form of programmed cell death that plays a critical role in the maintenance of tissue homeostasis [43]. It is a highly regulated physiologic mechanism that removes excess or damaged cells [43]. The dysregulation of apoptosis is a hallmark of cancer, with both the loss of pro-apoptotic signals and the gain of anti-apoptotic mechanisms contributing to tumorigenesis [44]. The induction of apoptosis in many cell types is achieved through the activation of the extrinsic and the intrinsic pathways [45]. The extrinsic pathway (Figure 1) is initiated by the interaction between specific ligands and surface receptors, such as CD95/Fas/Apo1, tumor necrosis factor (TNF) receptor 1 (TNFR1), TNF receptor 2 (TNFR2), and death receptors 3-6 (DR3-6) [46], which are able to deliver a death signal from the extracellular microenvironment to the cytoplasm. Binding of the ligand to the receptor induces receptor multimerization, binding of Fas-associated death domain (FADD) adapter protein, formation of the death-induced signaling complex (DISC) which recruits the initiator caspases 8 and 10, and subsequently activation of the effector caspases 3 and 7 [46]. In the intrinsic pathway (Figure 1), the integrity of the mitochondrial membrane is controlled primarily by a balance between the antagonistic actions of the proapoptotic and antiapoptotic members of the Bcl-2 family [47] (please see Table 1 for a detailed description of common abbreviations used in apoptosis). Bcl-2 family proteins comprise three principal subfamilies: (a) anti-apoptotic members, including Bcl-2/Bcl-xL, which possess the Bcl-2 homology (BH) domains BH1, BH2, BH3, and BH4; (b) pro-apoptotic members, such as Bax, Bak, and Bok, which have the BH1, BH2, and BH3 domains; and (c) BH3-only proteins, such as Bid, Bim, Bad, Bik, and Puma, which generally possess only the BH3 domain [47]. The Bcl-2 family of proteins regulates apoptosis by altering mitochondrial membrane permeabilization and controlling the release of cytochrome c. Several lines of evidence demonstrate that the Bcl-2 family functions are controlled by growth factor signaling pathways, including the PI3K/Akt, the JAK (Janus kinase)/Stat (signal transducer and activator of transcription), and the Ras/MAPK pathways [48]. Phosphorylation and dephosphorylation of the members of the Bcl-2 family of proteins by the above pathways regulate the stabilization of mitochondrial homeostasis [48].

**Signaling pathways implicated in estrogen-induced apoptosis**

The extrinsic (receptor-mediated) pathway

Mechanistic studies have used either LTED MCF-7 breast cancer cells [18,20,31,34] or selective ER modulator (SERM) (tamoxifen or raloxifene)-stimulated tumor models [23,35,36,49-51] to demonstrate the involvement of the Fas/FasL death signaling pathway in the paradoxical apoptotic/anti-tumor effects of E2. Song and colleagues [20] were the first to demonstrate that E2 caused apoptosis in breast cancer cells that were adapted to grow in an E2-free environment for prolonged periods. They reported that their LTED cells, which were derived by growing wild-type MCF-7 breast cancer cells under long-term (6 to 24 months) estrogen-deprived conditions, expressed high levels of Fas compared with the parental MCF-7 cells and that treatment of these cells with E2 resulted in a marked increase in FasL. This finding was confirmed by Osipo and colleagues [35], who reported that physiologic levels of E2 induced regression of tamoxifen-resistant breast cancer tumors by inducing Fas expression and suppressing the anti-apoptotic/pro-survival factors nuclear factor-kappa-B (NF-κB) and HER2/ neu. A similar finding was reported by Liu and colleagues [49] in raloxifene-resistant MCF-7 cells *in vitro* and *in vivo*. In addition, Tonetti and colleagues [50,51] previously reported that stable overexpression of protein kinase C-alpha (PKC-α) in hormone-responsive T47D:A18 breast cancer cells (T47D:A18/PKC-α) produced a hormone-independent/tamoxifen-resistant and E2-inhibitory phenotype *in vivo* [50,51]. Using the T47D:A18/PKC-α-overexpressing tumor model, they further demonstrated that E2-induced regression and apoptosis were due to increased expression of Fas/FasL proteins and downregulation of the pro-survival Akt pathway [36]. In all of these model systems, the ER-α was shown to be crucial for E2-induced tumor regression and apoptosis. Blockade of the ER-α signaling pathway using the pure anti-estrogen fulvestrant completely inhibited the apoptotic effect of E2 [20,35,36,49].

It is worth noting that a putative estrogen-responsive element (ERE) has been identified in the promoter region of the Fasl gene [52], suggesting direct estrogen effects on Fasl expression. In addition, a number of transactivating factors have been identified as regulators of Fasl gene expression, including activator protein 1 (AP-1) [53] and specificity protein 1 (Sp-1) [54]. Sp-1 is involved in the transcriptional regulation of many genes and also has been demonstrated to be important in the regulation of Fasl gene expression and apoptosis. Indeed, this transcription factor is able to activate Fasl promoter via a distinct recognition element, and inducible Fasl promoter activation is abrogated by the expression of the dominant-negative mutant form of Sp-1 [54]. Functional studies have demonstrated that Sp-1 is a crucial effector of E2 signal in enhancing Fasl gene expression. For instance, it is well known that ERs can transactivate gene promoters without directly binding to DNA...
but instead through interaction with other DNA-bound factors in promoter regions lacking TATA box. This has been investigated extensively in relation to protein complexes involving Sp-1 and ER-α at GC boxes, which are classic binding sites for members of the Sp-1 family of transcription factors. Sp-1 protein plays an important role in the regulation of mammalian and viral genes, and recent results have shown that E2 responsiveness of c-fos, cathepsin D, retinoic acid, and insulin-like growth factor-binding protein 4 gene expression in breast cancer cells is linked to specific GC-rich promoter sequences that bind ER/Sp-1 complex in which only Sp-1 protein binds DNA [55-59]. Thus, it is possible that, when E2 upregulates FasL production in these different model systems, an apoptotic signal is initiated by FasL binding on Fas receptor.

The intrinsic (mitochondrial) pathway
Over the last several years, there has been accumulating evidence that, apart from the extrinsic/receptor-mediated pathway, the mitochondrial (intrinsic) pathway plays a role in E2-induced apoptosis. Indeed, we [18] have previously reported that, in our LTED breast cancer cell line, MCF-7:5C, E2 treatment markedly increased the expression of several pro-apoptotic proteins, including, Bax, Bak, Bim, Noxa, Puma, and p53, and that blockade of Bax and Bim expression using short interfering RNAs (siRNAs) almost completely reversed...
the apoptotic effect of E2 in these cells. E2 treatment also led to a loss of mitochondrial potential and a dramatic increase in the release of cytochrome c from the mitochondria, which resulted in activation of caspases 7 and 9 and cleavage of poly(ADP-ribose)polymerase (PARP). Furthermore, overexpression of anti-apoptotic Bcl-xL completely blocked E2-induced apoptosis in MCF-7:5C cells. Interestingly, microarray analysis of wild-type MCF-7 cells and LTED MCF-7:5C cells revealed significant differences in the gene expression profile between the two cell lines following E2 treatment (Figure 2a). In particular, E2 treatment caused a marked increase in several pro-apoptotic genes in MCF-7:5C cells compared with wild-type MCF-7 cells (Figure 2b).

In two other estrogen-deprived breast cancer lines, LTED and E8CASS, basal Bcl-2 level was greatly elevated and knockdown of Bcl-2 expression with siRNA markedly sensitized these cells to the apoptotic action of E2 [32]. A similar finding was reported for another LTED breast cancer cell line, MCF-7:2A, which expressed elevated basal levels of Bcl-2 and was initially resistant to E2-induced apoptosis [34]. We found that suppression of Bcl-2 expression in these cells enhanced the apoptotic effect of E2 by almost fivefold [34], thus suggesting an important role for this protein in the apoptotic action of E2. Currently, there is renewed interest in developing small-molecule inhibitors of Bcl-2 [60] as anticancer cell and anti-angiogenic agents. The Bcl-2 antisense oligonucleotide, Oblimersen (Genasense; Genta Incorporated, Berkeley Heights, NJ, USA), which works by blocking Bcl-2 protein production, is now in a phase III clinical trial [61].

**Inhibition of the survival pathways Akt and nuclear factor-kappa-B**

The existence of various checkpoints in apoptosis reveals a complex balance between cell survival and cell death in cells. Two of the main signaling pathways involved in cell survival are the Akt and NF-κB signaling pathways (Figure 3). The PI3K/Akt/protein kinase B (PKB) pathway plays a central role in a variety of cellular processes, including cell growth, proliferation, motility, and survival in both normal and tumor cells. It impinges upon a remarkable array of intracellular events that influence either directly or indirectly whether a cell will undergo apoptosis. Many of the transforming events in breast cancer are a result of enhanced signaling of the PI3K/Akt pathway. Akt, also called PKB, is the human homologue of the viral oncogene v-akt [62], which regulates multiple targets, including several apoptotic genes. In a series of publications [63,64], Akt was found to mediate phosphorylation and hence inactivation of pro-apoptotic factors like Bad, which controls the release of cytochrome c.
procaspase 9, and Forkhead transcription factors. Akt also activates anti-apoptotic genes, including cyclic-AMP response element-binding protein (CREB) and IκB (inhibitor of NF-κB) kinase (IKK), the primary regulator of NF-κB activity.

Several groups have demonstrated that E2 can also inhibit the PI3K/Akt signaling pathway and consequently induce apoptosis of cancer cells. In tamoxifen-resistant PKC-α-overexpressing cells, E2-induced tumor regression is associated with the downregulation of phosphorylated Akt [36]. In addition, in LTED MCF-7:5C and MCF-7:2A breast cancer cells, the basal level of phosphorylated Akt is markedly upregulated and E2 treatment significantly reduces its expression (Figure 4). There is also evidence that, in MCF-7:beclin-overexpressing cells, E2 treatment significantly reduces Akt phosphorylation, which is associated with a decrease in cell proliferation [65]. Akt, therefore, is considered a rational target for cancer therapies and inhibitors of the PI3K/Akt pathway have been identified [66].

NF-κB is one of the most studied transcription factors in mammalian cells. Its family is composed of five members: RELA (p65), RELB, REL (cRel), NF-κB1 (p50 and its precursor p105), and NF-κB2 (p52 and its precursor p100) [67]. These proteins form homodimeric and heterodimeric complexes, and the activity of these proteins is regulated by two major pathways: the classical or canonical NF-κB activation pathway [67] and the non-canonical NF-κB activation pathway [67]. One of the most documented functions of NF-κB is its ability to promote cell survival through the induction of target genes (Figure 3), the products of which inhibit the apoptotic machinery in normal and malignant cells.

Figure 2

Gene expression profile of wild-type MCF-7 cells and long-term estrogen-deprived (LTED) MCF-7:5C breast cancer cells following 17β-estradiol (E2) treatment. Cells were treated with 1 nM E2 for 48 hours, and RNA was hybridized to the Affymetrix Human Genome U133 Plus 2.0 Arrays (Affymetrix, Santa Clara, CA, USA). (a) Hierarchical clustering dendogram of E2-regulated genes in MCF-7 and MCF-7:5C cells. Microarray expression data for each cell line were first filtered for minimal intra-replicate standard deviation (<0.25) and a standard deviation between all samples of at least 0.25. This generated a total of 2,743 genes. In addition, genes displaying a minimum of twofold upregulation or downregulation by E2 in either MCF-7 or MCF-7:5C cells were extracted, revealing a set of 539 differentially expressed, E2-regulated genes. (b) E2 regulation of pro-apoptotic and anti-apoptotic genes in MCF-7 cells (top panel) and MCF-7:5C cells (bottom panel). Bak, Bcl-2 homologous antagonist-killer protein; Bax, Bcl-2-associated X protein; Bcl-2, B-cell lymphoma-2; Bim, Bcl-2-interacting mediator of cell death; GADD45β, growth arrest and DNA damage; p53, 53 kDa protein.
Indeed, overall reduction in NF-κB activity is associated with an increased apoptotic index in many cell types [68]. Furthermore, NF-κB activation has been shown to inhibit p53-dependent apoptosis following expression of the oncogene AP12/MALT1 [69]. Thus, blocking this signaling pathway might be a promising option to improve the efficacy of conventional anti-cancer therapies.

Several studies have shown that E2 can inhibit the activity of NF-κB and thereby increase apoptosis. For example, Osipo and colleagues [35] reported that, in tamoxifen-resistant MCF-7 tumors, E2 treatment almost completely downregulated the level of the NF-κB p65 subunit protein, which correlated with the anti-proliferative and pro-apoptotic effects of E2 in this model system. These investigators also reported that cyclooxygenase 2 (COX-2), an NF-κB-responsive gene, was markedly reduced in E2-treated tamoxifen-stimulated MCF-7 tumors [35]. They concluded from this finding that E2-induced apoptosis and tumor regression in tamoxifen-resistant MCF-7 tumors occurred, in part, through suppression of the pro-survival/anti-apoptotic factor NF-κB. It should be noted that NF-κB expression is also markedly elevated in raloxifene-resistant MCF-7 breast cancer cells [49] and LTED breast cancer cells (Figure 4) and its downregulation by E2 is associated with the suppression of proliferation and the induction of apoptosis [31,32,70].

Glutathione suppression and estrogen-induced apoptosis

Previous studies have reported that, apart from its action on the mitochondria, Bcl-2 functions as an anti-oxidant to block apoptosis and that Bcl-2 protein levels and glutathione (GSH) intracellular concentration are coordinately regulated, with a decrease in either favoring cell death [71]. It is...
protein lysates were analyzed by Western blot for p-Akt, Akt, and breast cancer cells. Cells were treated with 1 nM E2 for 72 hours, and cells and long-term estrogen-deprived MCF-7:5C and MCF-7:2A

dlated Bcl-2 protein levels, mitochondrial membrane disruption associated with a marked decreased in Bcl-2 and phosphorylated Bcl-2 in MCF-7:2A cells and decreased phosphorylated c-jun in ER-positive MCF-7 breast cancer cells but not in ER-negative MDA-MB 231 cells, thus suggesting an ER-mediated event. Interestingly, when the JNK signaling pathway was disrupted by the JNK inhibitor SP600125, the ability of E2 to inhibit the growth of MCF-7 cells and to induce apoptosis was completely blocked. More recently, we reported that JNK activation (as measured by the increased levels of phospho-JNK1/2 and the JNK substrate phospho-c-Jun) was increased by low-dose E2 in the presence of BSO in anti-hormone-resistant MCF-7:2A cells [34]. While the exact mechanism by which JNK promotes apoptosis is not currently known, the phosphorylation of transcription factors such as c-jun and p53, as well as pro- and anti-apoptotic Bcl-2 family members, has been suggested to be of importance [81]. The treatment with BSO plus E2 markedly increased phosphorylated c-jun in MCF-7:2A cells and decreased phosphorylated Bcl-2 in these cells. These findings thus suggest that BSO plus E2 might mediate their apoptotic effect, in part, through activation of JNK.

Figure 4

|       | MCF-7 | 5C | 2A |
|-------|-------|----|----|
| Con   |       |    |    |
| E2    |       |    |    |
| pAkt(Ser473) | | | |
| Akt   |       |    |    |
| NF-κB |       |    |    |
| β-actin |       |    |    |

E2 (17β-estradiol) regulation of survival pathways in wild-type MCF-7 cells and long-term estrogen-deprived MCF-7:5C and MCF-7:2A breast cancer cells. Cells were treated with 1 nM E2 for 72 hours, and protein lysates were analyzed by Western blot for p-Akt, Akt, and nuclear factor-kappa-B (NF-κB). β-actin was used as a loading control.

GSH is a water-soluble tripeptide composed of glutamine, cysteine, and glycine. It is the most abundant intracellular small-molecule thiol present in mammalian cells, and it serves as a potent intracellular anti-oxidant, protecting cells from toxins such as free radicals [73]. Changes in GSH homeostasis have been implicated in the etiology and progression of a variety of human diseases, including breast cancer [74], and studies have shown that elevated levels of GSH prevent apoptotic cell death whereas depletion of GSH facilitates apoptosis [75]. L-buthionine sulfoximine (BSO) is a specific γ-glutamylcysteine synthetase inhibitor that blocks the rate-limiting step of GSH biosynthesis and, in doing so, depletes the intracellular GSH pool in both cultured cells and whole animals [73].

Recently, we reported that GSH participates in retarding apoptosis in anti-hormone-resistant LTED MCF-7:2A human breast cancer cells and that depletion of this molecule by BSO, a potent inhibitor of GSH biosynthesis, sensitized these resistant cells to E2-induced apoptosis [34]. GSH levels were elevated approximately 60% in MCF-7:2A cells compared with wild-type MCF-7 cells and these cells failed to undergo apoptosis following 1 week of E2 treatment. In the presence of BSO (100 μM), however, 1 nM E2 caused a dramatic increase in apoptosis which was observed as early as 48 hours, with maximum induction observed at day 7. The apoptotic effect of E2 plus BSO in MCF-7:2A cells was associated with a marked decrease in Bcl-2 and phosphorylated Bcl-2 protein levels, mitochondrial membrane disruption and cytochrome c release, caspase 7 activation, and PARP cleavage [34]. It is important to note that the concentration of BSO (100 μM) used in this study is clinically achievable without significant side effects [76]. Furthermore, early-phase clinical trials of BSO at doses resulting in both peripheral and tumor GSH depletion show that BSO can be safely administered with melphalan (L-PAM) to patients with refractory disease [77,78]. Thus, it is possible that future clinical studies of BSO infusions combined with low-dose estrogen hold the promise of improving disease control for patients with anti-hormone-resistant ER-positive metastatic breast cancer.

c-Jun N-terminal kinase signaling pathway

There is also evidence that E2 induces apoptosis by regulating the c-Jun N-terminal kinase (JNK) pathway. JNKs are a group of MAPKs that bind the NH2-terminal activation domain of the transcription factor c-jun and phosphorylate c-jun on amino acid residues Ser-63 and Ser-73 [79]. JNKs are stimulated by multiple factors, including cytokines, DNA-damaging agents, and environmental stresses, and are important in controlling programmed cell death or apoptosis. The inhibition of JNKs has been shown to enhance chemotherapy-induced inhibition of tumor cell growth, suggesting that JNKs may provide a molecular target for the treatment of cancer [79]. Recently, Altiok and colleagues [80] reported that, under low growth-stimulated conditions, high concentrations (1 μM) of E2 induced apoptosis and concurrently increased phosphorylation of c-jun in ER-positive MCF-7 breast cancer cells but not in ER-negative MDA-MB 231 cells, thus suggesting an ER-mediated event. Interestingly, when the JNK signaling pathway was disrupted by the JNK inhibitor SP600125, the ability of E2 to inhibit the growth of MCF-7 cells and to induce apoptosis was completely blocked. More recently, we reported that JNK activation (as measured by the increased levels of phospho-JNK1/2 and the JNK substrate phospho-c-Jun) was increased by low-dose E2 in the presence of BSO in anti-hormone-resistant MCF-7:2A cells [34]. While the exact mechanism by which JNK promotes apoptosis is not currently known, the phosphorylation of transcription factors such as c-jun and p53, as well as pro- and anti-apoptotic Bcl-2 family members, has been suggested to be of importance [81]. The treatment with BSO plus E2 markedly increased phosphorylated c-jun in MCF-7:2A cells and decreased phosphorylated Bcl-2 in these cells. These findings thus suggest that BSO plus E2 might mediate their apoptotic effect, in part, through activation of JNK.

Clinical exploitation of estrogen-induced apoptosis

Laboratory studies uniformly demonstrate that low concentrations of estrogen can cause apoptotic tumor cell death following profound estrogen deprivation with anti-hormones. The question that now needs to be answered is how can this new laboratory knowledge be translated into patient care?
Recently, Ellis and colleagues [42] reported that low-dose E2 (6 mg daily: 2 mg three times a day) produced a 25% response rate for patients with ER-positive AI-resistant advanced breast cancer. This number is slightly lower than the 31% objective response rate reported by Lonning and colleagues [40] with DES (5 mg three times a day) in post-menopausal women heavily pre-treated with endocrine therapy. The Lonning study [40] recruited patients with advanced breast cancer who were previously treated with exhaustive endocrine therapy. Of the 32 patients enrolled, four patients obtained complete response (CR) and six patients obtained partial response. In contrast, the Ellis study [42] recruited patients who were treated with an AI with 24 or more weeks of progression-free survival or who had a relapse after 2 or more years of adjuvant AI. Interestingly, there were no CRs in the Ellis study [42]. Clinical observations suggest that the duration of the post-menopausal period is one of the crucial factors affecting the success of low-dose estrogen therapy. In other words, the longer the estrogen deprivation period, the higher the likelihood of a response to low-dose estrogen. The fact that there were four CRs in the Lonning study [40] but none in the Ellis study [42] suggests the need for extensive estrogen blockade or withdrawal to get the best effects from low-dose estrogen.

**Estrogen and bone remodeling**

In addition to its role in female sexual development and reproductive physiology, estrogen plays a key role in bone cell metabolism. Estrogen contributes to the strength of a woman's skeleton by maintaining bone density. Bone is a dynamic tissue that is constantly being reshaped by osteoblasts, which build bone, and osteoclasts, which resorb bone [82]. This dynamic process is called remodeling. Osteoblasts are derived from pleiotropic mesenchymal stem cells in the bone marrow, whereas osteoclasts are multinuclear macrophage-like cells derived from hematopoietic stem cells also in the bone marrow. Bone resorption and deposition are tightly coupled, and their balance defines both bone mass as well as quality. The regulation of bone remodeling is complex; however, estrogen is thought to play a key role in this process [82]. Estrogen inhibits bone remodeling and bone resorption and enhances bone formation. Conversely, loss of estrogen, due to menopause or surgical oophorectomy, leads to an increased rate of remodeling and tilts the balance between bone resorption and formation in favor of the former [83]. Estrogen deficiency in post-menopausal women frequently leads to osteoporosis, the most common skeletal disorder. The imbalance in bone turnover that is induced by estrogen deficiency in women and female rodents can be ameliorated with estrogen/progestin hormone therapy or SERMs [84].

The main effect of estrogen on bone remodeling is to decrease activation frequency and subsequently decrease the numbers of osteoclasts and osteoblasts. Its effects on osteoclasts are mainly indirect and mediated by products secreted by the osteoblast. These products include RANK-L (the ligand of the receptor activator of NF-κB), colony-stimulating factor 1 (CSF-1), and osteoprotegerin (OPG). They regulate the differentiation of osteoclast precursors to osteoclasts and then modulate the activity of the mature osteoclasts and regulate its rate of apoptosis. Estrogen also decreases the secretion of the pro-inflammatory cytokines interleukin (IL) 1, IL-6, and TNF-α by marrow monocytes, resulting in decreased production of OPG and RANK-L by the osteoblasts, thereby decreasing the rate of production of osteoclasts, their activity, and their survival [82]. There is also evidence that estrogen has direct effects on osteoclast lineage cells. It induces apoptosis of these cells and it suppresses RANK-L-induced osteoclast differentiation by blocking RANK-L/macrophage colony-stimulating factor (M-CSF)-induced AP-1-dependent transcription through a reduction of c-jun activity [85]. Moreover, estrogen has been shown to inhibit the activity of mature osteoclasts through direct, receptor-mediated mechanisms. Indeed, a recent study by Nakamura and colleagues [86] reported that estrogen, acting via the ER-α, induced apoptosis in osteoclasts through activation of the Fas/FasL system and that this leads to suppression of bone resorption through truncating the short life span of differentiated osteoclasts.

**Future perspective**

Estrogen is a potent mitogen that stimulates cell proliferation and prevents cell death in breast cancer cells through activation of the ER. Paradoxically, estrogen is also capable of inducing tumor regression of hormone-dependent breast cancer in post-menopausal women who have been treated exhaustively with anti-hormones. Pre-clinical studies suggest that the evolution of anti-hormone resistance over years of therapy reconfigures the survival mechanism of the breast cancer cell so that estrogen no longer functions as a survival factor but as a death signal. It is this reconfiguration that helps to explain the 'two faces' of estrogen: the ability to stimulate growth and to induce death. Interestingly, estrogen also induces tumor regression in raloxifene-resistant endometrial tumors (G Balaburski and VC Jordan, personal communication) and it prevents bone loss by inducing apoptosis in osteoclasts, suggesting a universal principle.

Pre-clinical data [34] clearly show that it is possible to enhance the apoptotic effect of low-dose E2 by combining it with BSO. Hence, the combination of BSO and E2 could be used to improve the efficacy of E2 as an apoptotic agent if GSH depletion is fundamental to tumor cell survival. Phase I clinical trials of BSO at doses resulting in both peripheral and tumor GSH depletion show that BSO can be safely administered to patients with refractory disease. BSO was administered intravenously twice daily either alone or together with chemotherapy to cancer patients whose disease had progressed despite multiple lines of previous chemotherapy [78].

Inhibitors of survival pathways also have the ability to enhance the apoptotic/growth-inhibitory effects of E2. Several groups
have developed small-molecule inhibitors of Bcl-2 as anti-tumor agents [87]. These inhibitors encompass various drugs that bind the anti-apoptotic Bcl-2 family members with more or less efficacy. Oblimersen (Gensense; G3139) is an anti-Bcl-2 antisense oligonucleotide that has reached phase III clinical trials in combination therapy [88]. There are also natural inhibitors of Bcl-2, which include tea polyphenols such as catechins and theaflavins [89].

Conclusions
The discovery of a new biology of E2-induced apoptosis provides a unique signal transduction pathway to exploit in the treatment of metastatic breast cancer that has become refractory to exhaustive anti-hormone therapy. The clinical clues with the use of high-dose estrogen therapy have now been supported by a wealth of laboratory data defining apoptotic mechanisms. It is plausible to consider that the methodical evaluation of monoclonal antibodies and small-molecule tyrosine kinase inhibitors to prevent breast cancer survival could amplify the apoptotic actions of estradiol in a select group of patients. Indeed, if a study of the molecular biology of estrogen-induced apoptosis can define the mechanism precisely, then the molecules involved will become the target for a new drug group. These new drugs may be able to precipitate apoptosis in ER-negative breast tumors or indeed be used universally to treat cancer types other than breast cancer.

Competing interests
The authors declare that they have no competing interests.

Acknowledgments
This work was supported by National Institutes of Health Career Development Grant K01CA120051-01A2 (to JSL-W), American Cancer Society grant IRG-92-057-14 (JSL-W), the Hollenbach Family Fund (JSL-W), the Department of Defense Breast Cancer Program under award number BC050277 (to VCI), Center of Excellence SPORE (Specialized Program of Research Excellence) in Breast cancer grant CA 89018 (VCI), grant R01 GM067156 (VCI), Fox Chase Cancer Center Core Grant NIH P30, CA008927 (VCI), the Avon Foundation (VCI), the Genuardi’s Fund (VCI), and the Weg Fund of the Fox Chase Cancer Center (VCI).

References
1. Russo IH, Russo J: Role of hormones in mammary cancer initiation and progression. J Mammary Gland Biol Neoplasia 1998, 3:49-61.
2. Beatson CT: On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 1896, 2:101-111.
3. Beral V: Breast cancer and hormone-replacement therapy: a meta-analysis of 50,705 women in 53 epidemiological studies. Br J Cancer 1992, 66:1193-1209.
4. Schairer C, Linet MS, Fraumeni JF, Boyd NF, Devesa SS, Rosario R, Haenszel W: Breast cancer in women 50 years of age and older: a 30-year follow-up study. J Natl Cancer Inst 2003, 95:1378-1388.
5. Bast RC Jr: Estrogen-regulated developmental nodal apoptosis is determined by estrogen receptor subtype and the Fas/Fas ligand system. J Neurobiol 2000, 43:64-78.
6. Altucci L, Addeo R, Ciaciello L, Dauvois S, Parker MG, Truss M, Beato M, Sica V, Bresciani F, Weisz A: 17beta-Estradiol induces cyclin D1 gene transcription, p38 MAP kinase and p105RB phosphorylation during mitogenic stimulation of G1(1)-arrested human breast cancer cells. Oncogene 1996, 12:2315-2324.
7. Foster JS, Wimalasena J: Estrogen regulates activity of cyclin-dependent kinases and retinoblastoma protein phosphorylation in breast cancer cells. Mol Endocrinol 1996, 10:488-498.
8. Pietras RJ, Marquez-Garban DC: Membrane-associated estrogen receptor signaling pathways in human cancers. Clin Cancer Res 2007, 13:4672-4676.
9. Moriarty K, Kim KH, Bender JR: Minireview: estrogen receptor-mediated rapid signaling. Endocrinology 2006, 147:5557-5563.
10. Pedram A, Razandi M, Levin ER: Nature of functional estrogen receptors at the plasma membrane. Mol Endocrinol 2006, 20: 1996-2009.
11. Stoica GE, Franke TF, Wellstein A, Czubayko F, List HJ, Reiter R, Morgan M, Martin MB, Stoica A: Estradiol rapidly activates Akt via the ErbB2 signaling pathway. Mol Endocrinol 2003, 17:818-830.
12. Arpinio G, Wiechmann L, Osborne CK, Schiff R: Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev 2008, 29: 217-233.
13. Gompel A, Somai S, Chaouat M, Kazem A, Kloosterboer HJ, Beusman I, Forger P, Mimmoun M, Rostene W: Hormonal regulation of apoptosis in breast cells and tissues. Steroids 2000, 65:593-598.
14. Jordan VC: The 38th David A. Karnofsky lecture: the paradoxical actions of estrogen in breast cancer—survival or death? J Clin Oncol 2008, 26:3073-3082.
15. Jordan VC, Lewis JS, Osipo C, Cheng D: The apoptotic action of estrogen following exhaustive anti-hormonal therapy: a new clinical treatment strategy. Breast 2005, 14:624-630.
16. Jordan VC, Lewis JS, Cheng D, Jordan VC: Targeting oestrogen to kill the cancer but not the patient. Br J Cancer 2004, 90:944-949.
17. Lewis JS, Meeke K, Osipo C, Ross EA, Kidawi N, Li T, Bell E, Chandelier NS, Jordan VC: Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. J Natl Cancer Inst 2005, 97:1746-1759.
18. Santen RJ, Jenq MH, Wang JP, Song R, Masamura S, McPherson R, Santner S, Yue W, Shim WS: Adaptive hypersensitivity to estradiol: potential mechanism for secondary hormonal responses in breast cancer patients. J Steroid Biochem Mol Biol 2001, 78:115-123.
19. Santen RJ, Jenq MH, Wang JP, Song R, Masamura S, McPherson R, Santner S, Yue W, Shim WS: Adaptive hypersensitivity to estradiol: potential mechanism for secondary hormonal responses in breast cancer patients. J Steroid Biochem Mol Biol 2001, 78:115-123.
20. Song RX, Mor G, Naftolin F, McPherson RA, Song J, Zhang Z, Yue W, Wang J, Santen RJ: Effect of long-term estrogen deprivation on apoptotic responses in breast cancer cells. Breast Cancer Res 2001, 3:R1746-1759.
21. Swaby RF, Jordan VC: Low-dose estrogen therapy to reverse acquired antihormonal resistance in the treatment of breast cancer. Clin Breast Cancer 2008, 8:124-133.
28. Jiang SY, Jordan VC: Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor. J Natl Cancer Inst 1992, 84:580-591.

29. Levenson AS, Jordan VC: Transfection of human estrogen receptor (ER) cDNA into ER-negative mammalian cell lines. J Steroid Biochem Mol Biol 1994, 51:229-239.

30. Ingle JD, Ahmann DL, Green SJ, Edmonson JH, Bisel HF, Kvolts L, Nicholas WC, Creagan ET, Hahn RG, Rubin J, Frytak S: Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med 1981, 304:16:21.

31. Lewis JS, Osipo C, Meeko K, Jordan VC: Estrogen-induced aromatization in a mammary cell line transfected with human estrogen receptor gene. J Steroid Biochem Mol Biol 2005, 94:131-141.

32. Song RX, Zhang Z, Mor G, Santen RJ: Paradoxical action of fulvestrant in estrogen-reduced induced expression of tamoxifen-resistant breast cancer. J Natl Cancer Inst 2003, 95:1597-1608.

33. Zhang Z, Zhao H, Asztalos B, Chisamore MJ, Ahmed Y, Bentrem DJ, Jordan VC, Tonetti DA: Estrogen-inducible receptor alpha 1 gene expression: role of estrogen receptor-Sp1 complexes in vivo. Apoptotic action of diethylstilbestrol in estrogen receptor negative breast cancer cells transfected with complementary DNAs for estrogen receptor. J Natl Cancer Inst 1992, 84:580-591.

34. Chisamore MJ, Ahmed Y, Bentrem DJ, Jordan VC, Tonetti DA: Novel antitumor effect of estradiol in athymic mice injected with a T47D breast cancer cell line overexpressing protein kinase C. J Natl Cancer Inst 1995, 87:3156-3165.

35. Lu P, Jordan VC, Mor G, Santen RJ: Stable transfection of human breast cancer cells by estrogen: functional differences between estradiol and tamoxifen. J Steroid Biochem Mol Biol 2000, 73:185-194.

36. Kasibhatla S, Brunner T, Genestier L, Echeverri F, Mahboubi A, Grohe CR: DNA damage-stimulated apoptosis in aromatase inhibitor-positive breast cancer cells by estrogen: functional differences between estradiol and tamoxifen. J Steroid Biochem Mol Biol 2000, 73:185-194.

37. Haddow A, Watkinson JM, Paterson E: Estrogen receptor alpha 1 gene expression: role of estrogen receptor-Sp1 complexes in breast cancer cells transfected with complementary DNAs for estrogen receptor. J Natl Cancer Inst 1992, 84:580-591.

38. Santen RJ, Song RX, Masamura S, Yue W, Fan P, Sogon T, Hayashi S, Nakachi K, Eguchi H: Estrogen receptor alpha 1 gene expression: role of estrogen receptor-Sp1 complexes in breast cancer cells transfected with complementary DNAs for estrogen receptor. J Natl Cancer Inst 1992, 84:580-591.

39. Santen RJ, Song RX, Zhang Z, Mor G, Santen RJ: Paradoxical action of fulvestrant in estrogen-reduced induced expression of tamoxifen-resistant breast cancer. J Natl Cancer Inst 2003, 95:1597-1608.

40. Nuckel B, Suber SR, Lally M, Mor G, Santen RJ: Estrogen receptor-Sp1 complexes in breast cancer cells transfected with complementary DNAs for estrogen receptor. J Natl Cancer Inst 1992, 84:580-591.

41. Levenson AS, Jordan VC, Tonetti DA: Estrogen receptor alpha 1 gene expression: role of estrogen receptor-Sp1 complexes in breast cancer cells transfected with complementary DNAs for estrogen receptor. J Natl Cancer Inst 1992, 84:580-591.

42. Ingle JN, Ahmann DL, Green SJ, Edmonson JH, Bisel HF, Kvols L, Nicholas WC, Creagan ET, Hahn RG, Rubin J, Frytak S: Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med 1981, 304:16:21.

43. Lewis JS, Osipo C, Meeko K, Jordan VC: Estrogen-induced aromatization in a mammary cell line transfected with human estrogen receptor gene. J Steroid Biochem Mol Biol 2005, 94:131-141.

44. Song RX, Zhang Z, Mor G, Santen RJ: Paradoxical action of fulvestrant in estrogen-reduced induced expression of tamoxifen-resistant breast cancer. J Natl Cancer Inst 2003, 95:1597-1608.

45. Haddow A, Watkinson JM, Paterson E: Estrogen receptor alpha 1 gene expression: role of estrogen receptor-Sp1 complexes in breast cancer cells transfected with complementary DNAs for estrogen receptor. J Natl Cancer Inst 1992, 84:580-591.

46. Santen RJ, Song RX, Masamura S, Yue W, Fan P, Sogon T, Hayashi S, Nakachi K, Eguchi H: Estrogen receptor alpha 1 gene expression: role of estrogen receptor-Sp1 complexes in breast cancer cells transfected with complementary DNAs for estrogen receptor. J Natl Cancer Inst 1992, 84:580-591.

47. Santen RJ, Song RX, Zhang Z, Mor G, Santen RJ: Paradoxical action of fulvestrant in estrogen-reduced induced expression of tamoxifen-resistant breast cancer. J Natl Cancer Inst 2003, 95:1597-1608.

48. Haddow A, Watson JM, Paterson E: Influence of synthetic oestrogens upon advanced malignant disease. BMJ 1944, 2:393-398.

49. Carter AC, Sedransk N, Kelley RM, Anfield FJ, Ravdin RG, Talley RW, Potter NR: Diethylstilbestrol: recommended dosages for different categories of breast cancer patients. Report of the Cooperative Breast Cancer Group. JAMA 1977, 237:2079-2078.
71. Voehringer DW: BCL-2 and glutathione: alterations in cellular redox state that regulate apoptosis sensitivity. *Free Radic Biol Med* 1999, 27:945-950.

72. Ellerby LM, Ellerby HM, Park SM, Holleran AL, Murphy AN, Fiskum G, Kane DJ, Testa MP, Kayalar C, Bredesen DE: Shift of the cellular oxidation-reduction potential in neural cells expressing Bcl-2. *J Neurochem* 1996, 67:1259-1267.

73. Anderson CP, Tsai JM, Meek WE, Liu RM, Tang Y, Forman HJ, Reynolds CP: Depletion of glutathione by buthionine sulfoximine is cytotoxic for human neuroblastoma cell lines via apoptosis. *Exp Cell Res* 1999, 246:183-192.

74. Schroder CP, Godwin AK, O’Dwyer PJ, Tew KD, Hamilton TC, Ozols RF: *Glutathione and drug resistance*. *Cancer Invest* 1996, 14:158-168.

75. Schnelldorfer T, Gansauge S, Gansauge F, Schlosser S, Beger HG, Nussler AK: Glutathione depletion causes cell growth inhibition and enhanced apoptosis in pancreatic cancer cells. *Cancer* 2000, 89:1440-1447.

76. Bailey HH: L-S,R-buthionine sulfoximine: historical development and clinical issues. *Chem Biol Interact* 1998, 111-112:239-254.

77. Bailey HH, Mulcahy RT, Tutsch KD, Arzooomanian RZ, Alberti D, Tombes MB, Wilding G, Pomplum M, Spriggs DR: Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione. *J Clin Oncol* 1994, 12:194-205.

78. Bailey HH, Ripple G, Tutsch KD, Arzooomanian RZ, Alberti D, Feierabend C, Mahvi D, Schink J, Pomplum M, Mulcahy RT, Wilding G: Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan. *J Natl Cancer Inst* 1997, 89:1789-1796.

79. Vasilevskaya I, O’Dwyer PJ: Role of Jun and Jun kinase in resistance of cancer cells to therapy. *Drug Resist Updat* 2003, 6:147-156.

80. Altiok N, Koyuturk M, Altiok S: JNK pathway regulates estradiol-induced apoptosis in hormone-dependent human breast cancer cells. *Breast Cancer Res Treat* 2007, 105:247-254.

81. Park J, Kim I, Oh YJ, Lee K, Han PL, Choi EJ: Activation of c-Jun N-terminal kinase antagonizes an anti-apoptotic action of Bcl-2. *J Biol Chem* 1997, 272:16726-16728.

82. Riggs BL, Khosla S, Melton LJ 3rd: Sex steroids and the construction and conservation of the adult skeleton. *Endocr Rev* 2002, 23:279-302.

83. Teitelbaum SL: Osteoclasts: what do they do and how do they do it? Am J Pathol 2007, 170:427-435.

84. Delmas PD, Ensrud KE, Adachi JD, Harper KD, Sarkar S, Gennari C, Reginster JY, Pols HA, Becker RR, Harris ST, Wu W, Genant HK, Black DM, Eastell R: Multiple Outcomes of Raloxifene Evaluation Investigators: Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. *J Clin Endocrinol Metab* 2002, 87:3609-3617.

85. Srivastava S, Toraldo G, Weitzmann MN, Cenci S, Ross FP, Pacifici R: Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-kappa B ligand (RANKL)-induced JNK activation. *J Biol Chem* 2001, 276:8836-8840.

86. Nakamura T, Imai Y, Matsumoto T, Sato S, Takeuchi K, Igarashi K, Harada Y, Azuma Y, Krust A, Yamamoto Y, Nishina H, Takeda S, Takayanagi H, Metzger D, Kanno J, Martin TJ, Chambon P, Kato S: Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. *Cell* 2007, 130:811-823.

87. Zeitlin BD, Zeitlin U, Nor JE: Expanding circle of inhibition: small-molecule inhibitors of Bcl-2 as anticancer cell and antiangiogenic agents. *J Clin Oncol* 2008, 26:4180-4188.

88. Stein CA, Benimetskaya L, Mani S: *Antisense strategies for oncogene inactivation*. *Semin Oncol* 2005, 32:563-572.

89. Leone M, Zhai D, Sareth S, Kitada S, Reed JC, Pellecchia M: Cancer prevention by tea polyphenols is linked to their direct inhibition of antiapoptotic Bcl-2-family proteins. *Cancer Res* 2003, 63:8118-8121.